Rituxan (rituximab) - Roche
Longitudinal Anti-HBs Monitoring and Seroprotection Patterns in Rituximab-Treated Patients with Pemphigus Vulgaris: A Retrospective Cohort Study. (PubMed, Diagnostics (Basel)) - Sep 27, 2026 - " Quantitative anti-HBs levels varied significantly during follow-up; whereas, the probability of crossing below the conventional seroprotection threshold did not increase significantly. These findings support HBV serological assessment and cautious interpretation of serial anti-HBs measurements in rituximab-treated patients with pemphigus vulgaris." 
Journal • Retrospective data • Dermatology • Hepatitis B • Immunology • Infectious Disease • Inflammation • Pemphigus Vulgaris
http://www.ncbi.nlm.nih.gov/pubmed/42793789
 
Mehmet Harman; Nur Ecer
 
Sep 27, 2026
 
Prev Next